Astrazeneca (AZN) Equity Income (2015 - 2026)

Astrazeneca's Equity Income history runs 12 years deep, the most recent figure standing at -$12.0 million for Q1 2026.

• In Q1 2026, Equity Income fell 71.43% year-over-year to -$12.0 million; the TTM figure through Mar 2026 stood at -$12.0 million (up 45.45% YoY), while the FY2025 annual figure was -$7.0 million, up 75.0% from the prior year.
• Equity Income was -$12.0 million for Q1 2026 at Astrazeneca, down from $10.0 million in the prior quarter.
• In the past five years, Equity Income ranged from a high of $10.0 million in Q3 2025 to a low of -$13.0 million in Q1 2024.
• Historically, Equity Income has averaged -$4.6 million across 5 years, with a median of -$5.5 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Equity Income tumbled 1200.0% in 2023, then surged 350.0% in 2025.
• A 5-year view of Equity Income shows it stood at -$1.0 million in 2022, then sank by 1000.0% to -$11.0 million in 2023, then soared by 54.55% to -$5.0 million in 2024, then surged by 300.0% to $10.0 million in 2025, then tumbled by 220.0% to -$12.0 million in 2026.
• The last three Equity Income figures came in at -$12.0 million (Q1 2026), $10.0 million (Q3 2025), and -$10.0 million (Q2 2025), per Business Quant data.